Cas:147539-21-7 3-pyridylamine, n-(1-methylethyl)-2-(1-piperazinyl)-,dihydrochloride monohydrate manufacturer & supplier

Chemical Name:3-pyridylamine, n-(1-methylethyl)-2-(1-piperazinyl)-,dihydrochloride monohydrate

CAS.NO:147539-21-7

Synonyms:dihydrochloride,monohydrate;3-isopropylamino-2-piperazinylpyridine

Molecular Formula:C₁₂H₂₄Cl₂N₄O

Molecular Weight:311.25100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:49.42000

Exact Mass:310.13300

LogP:3.31800

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like dihydrochloride,monohydrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-isopropylamino-2-piperazinylpyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-isopropylamino-2-piperazinylpyridine Use and application,3-isopropylamino-2-piperazinylpyridine technical grade,usp/ep/jp grade.

Related News: The fine and functional chemicals sector provides new growth drivers. 3-pyridylamine, n-(1-methylethyl)-2-(1-piperazinyl)-,dihydrochloride monohydrate manufacturer Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. 3-pyridylamine, n-(1-methylethyl)-2-(1-piperazinyl)-,dihydrochloride monohydrate supplier Eli Lilly and Roche have been riding high this week on the controversial approval of Biogen’s anti-amyloid Alzheimer’s disease drug Aduhelm (aducanumab), as its new low bar could help these Big Pharmas jump the finish line. 3-pyridylamine, n-(1-methylethyl)-2-(1-piperazinyl)-,dihydrochloride monohydrate vendor That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. 3-pyridylamine, n-(1-methylethyl)-2-(1-piperazinyl)-,dihydrochloride monohydrate factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.